Jamie Madrigal And The Team – Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
Jamie Madrigal, Scientist at Certara, shared a post by Journal of Thrombosis and Haemostasis on LinkedIn:
”Excited to share that my PhD research on emicizumab was recently published.”
Quoting Journal of Thrombosis and Haemostasis’s post:
”Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions
This study used mathematical modeling and biochemical assays to dissect how emicizumab, a bispecific antibody bridging activated factor IXa and factor X, functions differently from factor VIII. It revealed that high emicizumab levels inhibit factor X activation via tissue factor pathway due to reduced lipid surface binding but enhance factor IXa-dependent activation of factor X on lipid surfaces. The model provides kinetic estimates and explains emicizumab’s mechanism of enhancing coagulation through lipid-surface interactions.
Read this paper here.
Title: Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions
Authors: Jamie Madrigal, Dougald Monroe, Suzanne Sindi, Karin Leiderman”
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia